UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month May 2018
(Commission File No. 001-35193)
Grifols, S.A.
(Translation of registrant’s name into English)
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles 08174
Barcelona, Spain
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ¨ No x
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes o No x
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- . .
Grifols, S.A.
Item |
|
|
| Sequential Page Number |
|
|
|
|
|
|
| 3 |
Grifols, S.A. Avinguda de Ia General itat 152-158 08174 Sant Cugat del Valles Barcelona-ESPANA Tel. [34] 935 710 500 Fax [34J 935 710 267 www.grifols.com GRIFOLS Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following RELEVANTEVENT Grifols has entered into an agreement with Chinese based Jiangxi Boya Bio Pharmaceutical Co. Ltd. whereby both parties have agreed to jointly collaborate to build and manage a significant number of plasma collection centres throughout the territory of the People's Republic of China. In accordance with current applicable laws, all collected plasma by the collection centres built under this project will be supplied to Boya. This notwithstanding, Grifols has reserved the right to have access to up to 50% of the collected plasma by each plasma collection centre, if and when permitted by applicable laws. The initial investment for the project is EUR 50 million. In Barcelona, on 10 May 2018 Nuria Martin Barnes Secretary to the Board of Directors
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
| Grifols, S.A. | ||
|
| ||
|
| ||
| By: | /s/ David I. Bell | |
|
| Name: | David I. Bell |
|
| Title: | Authorized Signatory |
|
| ||
Date: May 10, 2018 |
|